Acetylcholinesterase inhibitors rapidly activate Trk neurotrophin receptors in the mouse hippocampus
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Acetylcholinesterase inhibitors are first-line therapies for Alzheimer's disease. These drugs increase cholinergic tone in the target areas of the cholinergic neurons of the basal forebrain. Basal forebrain cholinergic neurons are dependent upon trophic support by nerve growth factor (NGF) through its neurotrophin receptor, TrkA. In the present study, we investigated whether the acetylcholinesterase inhibitors donepezil and galantamine could influence neurotrophin receptor signaling in the brain. Acute administration of donepezil (3 mg/kg, i.p.) led to the rapid autophosphorylation of TrkA and TrkB neurotrophin receptors in the adult mouse hippocampus. Similarly, galantamine dose-dependently (3, 9 mg/kg, i.p.) increased TrkA and TrkB phosphorylation in the mouse hippocampus. Both treatments also increased the phosphorylation of transcription factor CREB and tended to increase the phosphorylation of AKT kinase but did not alter the activity of MAPK42/44. Chronic treatment with galantamine (3 mg/kg, i.p., 14 days), did not induce changes in hippocampal NGF and BDNF synthesis or protein levels. Our findings show that acetylcholinesterase inhibitors are capable of rapidly activating hippocampal neurotrophin signaling and thus suggest that therapies targeting Trk signaling may already be in clinical use in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 3×
“The AChEi-induced changes in Trk receptor phosphorylation were accompanied by an increase in the phosphorylation of AKT, which is a downstream target of Trk signaling implicated in neuronal survival (Chao, 2003; Takada-Takatori et al., 2006).”
BackgroundMethodSelf-citationCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906 · cited 2×
“Current first-line medications of AD are AChEis which can improve the cognitive capabilities in patients with mild to moderate AD (Birks, 2006).”
Bourtchuladze, R., Frenguelli, B., Blendy, J., Cioffi, D., Schutz, G., & Silva, A. J. (1994) · Cell · doi:10.1016/0092-8674(94)90400-6 · Cited by 1,800 · cited 1×
“In addition, both donepezil and galantamine increased the phosphorylation of transcription factor CREB which is crucial for TrkB edependent hippocampal learning (Bourtchuladze et al., 1994; Minichiello, 2009).”
BackgroundTrkB signalling pathways in LTP and learning
Minichiello, L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2738 · Cited by 1,055 · cited 1×
“In addition, both donepezil and galantamine increased the phosphorylation of transcription factor CREB which is crucial for TrkB edependent hippocampal learning (Bourtchuladze et al., 1994; Minichiello, 2009).”
BackgroundSaarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Rantamäki, T., Hendolin, P., Kankaanpää, A., Mijatovic, J., Piepponen, P., Domenici, E., Chao, M. V., Männistö, P. T., & Castrén, E. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301345 · Cited by 305
Self-citationMorse, J., Wiegand, S., Anderson, K., You, Y., Cai, N., Carnahan, J., Miller, J., DiStefano, P., Altar, C., & Lindsay, R. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04146.1993 · Cited by 251 · cited 2×
“neurotrophic factor (BDNF), has similar effects on ChAT activity and BFCN survival (Alderson et al., 1990; Morse et al., 1993; Widmer et al., 1993).”
BackgroundKoponen, E., Võikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, H., Taira, T., & Castrén, E. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.01.006 · Cited by 170 · cited 3×
“terminally FLAG-sequence tagged full-length TrkB receptor (Koponen et al., 2004)”
MethodInfluentialJang, S.-W., Liu, X., Chan, C.-B., Weinshenker, D., Hall, R. A., Xiao, G., & Ye, K. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.010 · Cited by 144 · cited 1×
“It has also been suggested that some neuropsychiatric drugs could directly bind to Trk receptors (Jang et al., 2009).”
Background
Cited by
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
TrkB Receptor Signalling: Implications in Neurodegenerative, Psychiatric and Proliferative Disorders
Gupta, V., You, Y., Gupta, V., Klistorner, A., & Graham, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140510122 · Cited by 258
Nabel, E. M., & Morishita, H. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00146 · Cited by 85
“(D) Interventions for fear erasure in the adult: juvenile-like plasticity can be reintroduced in adulthood through pharmacological treatment (ChABC, SSRI treatment) or reconsolidation update.”
BackgroundInfluentialTrkB neurotrophin receptor at the core of antidepressant effects, but how?
Rantamäki, T. (2019) · Cell and Tissue Research · doi:10.1007/s00441-018-02985-6 · Cited by 45
Self-citationAtta, A. A., Ibrahim, W. W., Mohamed, A. F., & Abdelkader, N. F. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175810 · Cited by 29
Metadata
- Authors
- Autio, H., Mätlik, K., Rantamäki, T., Lindemann, L., Hoener, M. C., Chao, M., Arumäe, U., & Castrén, E.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 61
- Issue
- 8
- Pages
- 1291-1296
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1991798750
- Cited by
- 46
- References
- 11
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.